Compare iShares Bitcoin Trust (IBIT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Novo Nordisk A/S — how do they compare? iShares Bitcoin Trust trades at $46.55 (market cap $67.31B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.5× iShares Bitcoin Trust's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Novo Nordisk A/S for 116 Days on average.
| IBIT | NVO | |
|---|---|---|
Market Cap | $67.31B | $165.31B |
Volume | 56,154,544 | 11,432,838 |
Sector | Crypto-linked | Health |
52-Week High | $66.20 | $63.98 |
52-Week Low | $33.29 | $35.29 |
Typical Hold Time | 40 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.26, down 2.01% today amid bearish technical signals. The stock faces resistance at $47-$48 with support at $44-$46. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026, reflecting renewed investor confidence despite current price weakness.
The outlook remains cautious with technical indicators showing bearish momentum, though strong institutional interest suggests potential recovery. Key risks include market volatility and ETF fee structures, while analyst sentiment appears mixed with ongoing monitoring of Bitcoin market dynamics influencing stock performance.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
